Insilico Medicine
IntegratedApplied AIPublic · 3696.HKUpdated November 15, 2026The only AI-designed drug in Phase II clinical trials — a genuine milestone in AI-driven drug discovery.
- Website
- insilico.com
- Founded
- 2014
- CEO
- Alex Zhavoronkov
- HQ
- Cambridge, Hong Kong
- Stage
- Public
- Revenue
- $50M–$100M
- Employees
- 201-500
Executive Summary
Updated Nov 15, 2026
What they do
- Generative AI drug discovery covering target identification, molecule design and clinical prediction
- Licenses its Pharma.AI software suite, including PandaOmics, Chemistry42 and inClinico, to pharma R&D teams
- Develops its own pipeline, led by rentosertib, a TNIK inhibitor for IPF now in Phase III
Why it matters
- Rentosertib is the first generative-AI-discovered drug to reach a Phase III trial
- About US$7.3B in disclosed deal value signed in 2026, including SK Biopharmaceuticals and Takeda
- H1 2026 revenue was US$106.3M, up 287%, and the company turned a net profit
Best fit
- Large pharma looking for AI co-discovery deals with milestone-based economics
- Biotech R&D teams that want licensed generative chemistry and target-discovery software
- Companies working in fibrosis, oncology, CNS or immunology that want faster candidate nomination
Watch-outs
- Revenue depends on upfront and milestone payments that can swing from period to period
- Rentosertib's Phase III result is pending, so the clinical validation is not yet final
- Much of its R&D runs in China, which may draw geopolitical and data-governance scrutiny
Products & Offerings
Pharma.AI
End-to-end generative AI drug discovery platform covering biology, chemistry and clinical development, offered by license and through partnerships.
Chemistry42
Generative chemistry engine that designs and optimizes novel small molecules with target properties.
PandaOmics
AI target discovery engine that analyzes multi-omics data and literature to rank novel therapeutic targets.
inClinico
Predictive model that estimates the likelihood that clinical trials will succeed, for portfolio and trial-design decisions.
Rentosertib (ISM001-055)
Oral TNIK inhibitor for idiopathic pulmonary fibrosis, discovered with AI and now in the Phase III GENESIS-IPF-3 trial.
Recent Releases
- Longevity GrokModelNewsNov 2026
Latest News
Bioengineer.org · 2 days ago
PositiveEurekAlert! · 2 days ago
NeutralInsilico Medicine · 3 days ago
PositiveOncodaily · 5 days ago
PositiveDrug Discovery & Development · 7 days ago
PositiveUpdated Nov 15, 2026
Insilico is the most clinically advanced generative-AI drug discovery company: it has a Phase III asset, several big-pharma deals in 2026 and now reports a profit. Pharma and biotech R&D leaders looking for AI co-discovery partners or generative chemistry software should include it in their evaluations. Before signing, check how IP and milestones are structured, and assess China data-residency and supply-chain exposure.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 5, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 15, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 15, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Oct 31, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | SEC filings |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 15, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Insilico Medicine's Bluescore of 48.2 rests most on Data & Model Moat (8.6, top 2%) and Talent & Research (5.6, 67th percentile). Its weakest area is Customer Adoption (4.0, 9th percentile).
In plain English
Insilico Medicine's Bluescore of 48.2 is held up mainly by Data & Model Moat, where its score of 8.6 of 10 sits at the 98th percentile and adds 16.3 of 19 possible points. The biggest drags are Product Depth, which scores 3.1 of 10 (18th percentile) and adds only 6.6 of 21 points, and Investment Momentum, which scores 2.1 of 10 (11th percentile). Product Depth would move the score most, since it carries a 21% weight and still has 14.4 points left to gain.
Written by AI from the scores below and checked against them; updated nightly.
Traction Signals
Last Round
Public
Risks
Updated Nov 15, 2026